glucagon — 17 things I got wrong before I got it right
Quick one. Canada here.
MASH works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.
Specifics: the route I used took 13 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.
Happy to answer questions from anyone in the same jurisdiction.
best — the order this archive was captured in
The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.
The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.
Retitled to remove editorialising. Put the evidence in the body.
The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.
Adding to this: biopsy is doing more work than the comment implies.
not approved, descriptive posts only
Disagree but this is the good kind of wrong — it is specific enough to be checked.
Disagree but this is the good kind of wrong — it is specific enough to be checked.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
the safety profile is not just tirzepatide amplified
Every time this gets posted it hits the front page and every time someone has to re-explain it.
This is correct. Do not generalise from tirzepatide.
Yeah, glucagon co-agonism is genuinely different.
New Zealand here. Waited 9 months on a list, gave up, went private, and the total cost was roughly what I expected.
New Zealand here.
Disagree on that part. 96.8% and 96.2% on the same vial is normal.
This is correct. Do not generalise from tirzepatide.
Small correction: the trial was 7 weeks, not 7. Does not change your point but people will quote it.
Strongly agree. The safety story is separate.
This is correct. Do not generalise from tirzepatide.
the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1
do not generalise from tirzepatide
phase 16 data is interesting, phase 4 will be different
Which trial arm?
the safety profile is not just tirzepatide amplified
Yeah, glucagon co-agonism is genuinely different.
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
- 1The evidence standard in c/vendorvetting gets called too strict about once a…8 comments in this branch · started by u/renal_outcomes_r
- 2This is correct. Do not generalise from tirzepatide.8 comments in this branch · started by u/peak_area_pete